<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868409</url>
  </required_header>
  <id_info>
    <org_study_id>H-20074958</org_study_id>
    <nct_id>NCT04868409</nct_id>
  </id_info>
  <brief_title>Intubating Conditions During Rapid Sequence Induction in Elderly With Either Suxamethonium 1.0 mg/kg or Rocuronium 1.0 mg/kg</brief_title>
  <official_title>A Single Blinded Multicenter Randomized Study Comparing Intubating Conditions During Rapid Sequence Induction With Either Suxamethonium 1.0 mg/kg or Rocuronium 1.0 mg/kg in Elderly Patients (≥ 80 Years Old)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matias Vested</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the proportion of excellent tracheal intubation&#xD;
      conditions at 60 seconds after administration of either rocuronium 1.0 mg/kg or suxamethonium&#xD;
      1 mg/kg in patients with age ≥ 80 years during rapid sequence induction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elderly patients are frail and susceptible to complications in the perioperative period. They&#xD;
      are at higher risk of major morbidity and mortality and are characterized by a reduction in&#xD;
      cardiac output, liver function and renal function. These physiological changes influence&#xD;
      pharmacodynamics and pharmacokinetics of drugs administered during anesthesia as for example&#xD;
      neuromuscular blocking agents (NMBA).&#xD;
&#xD;
      The number of elderly patients (&gt;80 years) is increasing and a large proportion of these&#xD;
      patients will require surgery and anesthesia with employment of rapid sequence induction&#xD;
      (RSI) within the next decades. RSI and intubation is performed when there is an increased&#xD;
      risk of pulmonary aspiration of gastric contents. Because of its fast onset time&#xD;
      succinylcholine is often used to facilitate tracheal intubation during RSI. However,&#xD;
      succinylcholine has certain side effects such as cardiac arrhythmia, hyperkalemia, muscle&#xD;
      soreness, short duration of action and shorter time to desaturation.&#xD;
&#xD;
      It is therefore unknown if succinylcholine 1.0 mg/kg provides better intubating conditions&#xD;
      compared to high dose rocuronium (1.0 mg/kg) in the elderly. In this matter, there remains a&#xD;
      need for a study to investigate the optimal muscle relaxant during rapid sequence induction&#xD;
      for facilitating tracheal intubation in the elderly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation conditions</measure>
    <time_frame>60 seconds after induction of anaesthesia</time_frame>
    <description>Tracheal intubating conditions according to the Fuchs-Buder scale: Excellent, good or poor depending on laryngoscopy, vocal chords and reaction to intubation,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tracheal intubation</measure>
    <time_frame>within 15 minutes after administration of muscle relaxant</time_frame>
    <description>• Time to tracheal intubation (from administration of muscle relaxant till correct placement of tracheal tube)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to TOF count 0</measure>
    <time_frame>within 15 minutes</time_frame>
    <description>Time till no response from the nerve-stimulator after administration of muscle relaxant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First pas succes rate</measure>
    <time_frame>within 15 minutes</time_frame>
    <description>Succes of tracheal tube placement 60 seconds after administration of muscle relaxant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation conditions</measure>
    <time_frame>within 15 minutes</time_frame>
    <description>Intubation conditions evaluated on the Intubation Difficulty Scale ranging from 0 (best) til 10 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desaturation</measure>
    <time_frame>within 15 minutes</time_frame>
    <description>spO2 &lt; 0.9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac arrythmia</measure>
    <time_frame>within 15 minutes of anesthesia</time_frame>
    <description>Occurrence of new cardiac arrythmia during induction of anaesthesia (&lt;15 minutes from administration of muscle relaxant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sore throat</measure>
    <time_frame>24 hours after anaesthesia</time_frame>
    <description>blinded assessment of sore throat reported by the patient on a numerical ranking scale (0 best, 10 worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle soreness</measure>
    <time_frame>24 hours after anaesthesia</time_frame>
    <description>blinded assessment of muscle soreness reported by the patient on a numerical ranking scale (0 best, 10 worst)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Intubation Conditions</condition>
  <arm_group>
    <arm_group_label>Rocuronium group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suxamethonium group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Suxamethonium 1 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suxamethonium</intervention_name>
    <description>1 mg/kg for tracheal intubation after 60 seconds</description>
    <arm_group_label>Suxamethonium group</arm_group_label>
    <other_name>Succinylcholine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>1 mg/kg for tracheal intubation after 60 seconds</description>
    <arm_group_label>Rocuronium group</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 80&#xD;
&#xD;
          -  Scheduled for surgery under general anesthesia with indication for rapid sequence&#xD;
             induction&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status classification (ASA) I to IV&#xD;
&#xD;
          -  Informed consent (see appendix 1)&#xD;
&#xD;
          -  Body mass index (BMI) &lt; 35 kg/m2&#xD;
&#xD;
          -  Read and understand Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neuromuscular disease&#xD;
&#xD;
          -  Known allergy to rocuronium and/or suxamethonium&#xD;
&#xD;
          -  Known hyperkalemia &gt; 5 mM&#xD;
&#xD;
          -  Previous malignant hyperthermia&#xD;
&#xD;
          -  Known homozygote plasmacholinesterase gene mutation variant a or s&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars S Rasmussen</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matias Vested</last_name>
    <phone>+4535457547</phone>
    <email>matias.vested@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2830</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matias Vested, MD</last_name>
      <email>matias.vested@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Meyhoff, MD</last_name>
      <email>christian.sylvest.meyhoff@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roar Medici, MD</last_name>
      <email>roar.medici@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Matias Vested</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

